276 related articles for article (PubMed ID: 36695097)
41. Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States.
Smith TJ; Cockerham K; Lelli G; Choudhary C; Taylor S; Barretto N; Enstone A; Oliver L; Lynch J; Holt RJ
JAMA Ophthalmol; 2023 Feb; 141(2):159-166. PubMed ID: 36580313
[TBL] [Abstract][Full Text] [Related]
42. [Monoclonal antibodies in the treatment of thyroid eye disease].
Cheredanova VR; Poteshkin YE
Vestn Oftalmol; 2021; 137(4):116-122. PubMed ID: 34410066
[TBL] [Abstract][Full Text] [Related]
43. Teprotumumab for the treatment of Thyroid eye disease.
Ugradar S; Malkhasyan E; Douglas RS
Endocr Rev; 2024 Jun; ():. PubMed ID: 38838219
[TBL] [Abstract][Full Text] [Related]
44. A comparison of proptosis reduction with teprotumumab versus surgical decompression based on fat-to-muscle ratio in thyroid eye disease.
Ting MAJ; Topilow NJ; Ediriwickrema LS; Yoon JS; Liu CY; Korn BS; Kikkawa DO
Orbit; 2024 Apr; 43(2):222-230. PubMed ID: 37978819
[TBL] [Abstract][Full Text] [Related]
45. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
Kossler AL; Douglas R; Dosiou C
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
[TBL] [Abstract][Full Text] [Related]
46. Teprotumumab in thyroid eye disease.
Goldberg H; Malik AI
Saudi J Ophthalmol; 2024; 38(1):29-33. PubMed ID: 38628412
[TBL] [Abstract][Full Text] [Related]
47. A Review of Novel Medical Treatments for Thyroid Eye Disease.
Park JW; Yoon JS
Korean J Ophthalmol; 2024 Jun; 38(3):249-259. PubMed ID: 38773958
[TBL] [Abstract][Full Text] [Related]
48. Updates on the understanding and management of thyroid eye disease.
Men CJ; Kossler AL; Wester ST
Ther Adv Ophthalmol; 2021; 13():25158414211027760. PubMed ID: 34263138
[TBL] [Abstract][Full Text] [Related]
49. Differential effects of teprotumumab treatment based on fat-to-muscle ratio in patients with thyroid eye disease.
Ting MA; Ozzello DJ; Topilow NJ; Yoon JS; Liu CY; Korn BS; Kikkawa DO
Orbit; 2023 Aug; 42(4):418-425. PubMed ID: 36097675
[TBL] [Abstract][Full Text] [Related]
50. Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators.
Douglas RS; Wang Y; Dailey RA; Harris GJ; Wester ST; Schiffman JS; Tang RA; Fowler B; Fleming J; Smith TJ
J Neuroophthalmol; 2021 Dec; 41(4):461-468. PubMed ID: 33417417
[TBL] [Abstract][Full Text] [Related]
51. Echographic Assessment of Extraocular Muscle Response to Teprotumumab.
Tran C; Pham CM; Simmons BA; Warner LL; Fuhrmeister LJ; Shriver EM
Ophthalmic Plast Reconstr Surg; 2022 Jul-Aug 01; 38(4):336-339. PubMed ID: 34652310
[TBL] [Abstract][Full Text] [Related]
52. Teprotumumab in thyroid eye disease: wonder drug or great divider?
Perros P; Hegedüs L
Eur Thyroid J; 2023 Aug; 12(4):. PubMed ID: 37043369
[TBL] [Abstract][Full Text] [Related]
53. Inflammatory and Noninflammatory Thyroid Eye Disease: Comparison of Disease Signs, Symptoms, and Quality of Life in Patients in the United States.
Wang Y; Padnick-Silver L; Francis-Sedlak M; Holt RJ; Foley C; Douglas RS
Endocr Pract; 2022 Sep; 28(9):842-846. PubMed ID: 35714862
[TBL] [Abstract][Full Text] [Related]
54. Successful Case of Teprotumumab Treatment in an Adolescent Patient With Thyroid Eye Disease.
Radulovich N; Van Brummen A; Chambers C; Zhang M
Ophthalmic Plast Reconstr Surg; 2024 Mar-Apr 01; 40(2):e65-e67. PubMed ID: 38231594
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.
Krieger CC; Sui X; Kahaly GJ; Neumann S; Gershengorn MC
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1653-e1660. PubMed ID: 34788857
[TBL] [Abstract][Full Text] [Related]
56. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series.
Chu M; Sung J; Song M; Song A; Song J
J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553
[TBL] [Abstract][Full Text] [Related]
57. Teprotumumab and Orbital Decompression for the Management of Proptosis in Patients With Thyroid Eye Disease.
Hubschman S; Sojitra B; Ghiam S; Sears C; Hwangbo N; Goldberg RA; Rootman DB
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):270-275. PubMed ID: 37972968
[TBL] [Abstract][Full Text] [Related]
58. Teprotumumab for the treatment of thyroid eye disease.
Ju Y; Yang J
Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
[TBL] [Abstract][Full Text] [Related]
59. Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach.
Douglas RS; Kossler AL; Abrams J; Briceño CA; Gay D; Harrison A; Lee M; Nguyen J; Joseph SS; Schlachter D; Tan J; Lynch J; Oliver L; Perry R; Ugradar S
J Neuroophthalmol; 2022 Sep; 42(3):334-339. PubMed ID: 35421877
[TBL] [Abstract][Full Text] [Related]
60. The "Quiet TED"-A Special Subgroup of Thyroid Eye Disease.
Iñiguez-Ariza NM; Sharma A; Garrity JA; Stan MN
Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):551-555. PubMed ID: 33782324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
